Crispr Therapeutics (NASDAQ:CRSP) Price Target Raised to $128.00 at Piper Sandler

Crispr Therapeutics (NASDAQ:CRSP) had its price target upped by Piper Sandler from $104.00 to $128.00 in a report released on Wednesday morning, The Fly reports. The brokerage currently has an overweight rating on the stock.

A number of other equities analysts also recently weighed in on the company. William Blair reiterated a buy rating on shares of Crispr Therapeutics in a report on Tuesday, July 28th. Wells Fargo & Company increased their price objective on Crispr Therapeutics from $95.00 to $110.00 and gave the stock an overweight rating in a report on Tuesday, July 28th. SunTrust Banks assumed coverage on Crispr Therapeutics in a report on Tuesday, July 14th. They issued a buy rating and a $140.00 price objective on the stock. Chardan Capital increased their price objective on Crispr Therapeutics from $72.50 to $100.00 and gave the stock a buy rating in a report on Tuesday, July 28th. Finally, BidaskClub upgraded Crispr Therapeutics from a hold rating to a buy rating in a report on Wednesday, September 2nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and fifteen have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $101.41.

Shares of CRSP opened at $92.65 on Wednesday. The company has a market capitalization of $6.50 billion, a price-to-earnings ratio of 201.41 and a beta of 2.31. Crispr Therapeutics has a fifty-two week low of $32.30 and a fifty-two week high of $111.90. The business’s 50-day moving average is $89.23 and its 200-day moving average is $76.02.

Crispr Therapeutics (NASDAQ:CRSP) last issued its earnings results on Monday, July 27th. The company reported ($1.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.35). The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $19.77 million. Crispr Therapeutics had a net margin of 6.77% and a return on equity of 2.35%. Crispr Therapeutics’s revenue for the quarter was down 86.2% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.01) EPS. On average, equities analysts predict that Crispr Therapeutics will post -4.72 earnings per share for the current year.

In other news, Director Bradley J. Phd Bolzon sold 1,155 shares of the stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $84.89, for a total value of $98,047.95. Following the completion of the sale, the director now directly owns 7,391 shares of the company’s stock, valued at $627,421.99. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Bradley J. Phd Bolzon sold 60,000 shares of the firm’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $92.51, for a total value of $5,550,600.00. The disclosure for this sale can be found here. Insiders sold 133,000 shares of company stock valued at $12,064,743 over the last three months. 21.40% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of the stock. State Street Corp increased its position in Crispr Therapeutics by 48.2% in the first quarter. State Street Corp now owns 71,211 shares of the company’s stock worth $3,020,000 after buying an additional 23,159 shares during the last quarter. Geode Capital Management LLC increased its holdings in Crispr Therapeutics by 9.5% in the first quarter. Geode Capital Management LLC now owns 42,950 shares of the company’s stock worth $1,821,000 after buying an additional 3,716 shares during the last quarter. Morgan Stanley increased its holdings in Crispr Therapeutics by 233.6% in the first quarter. Morgan Stanley now owns 851,519 shares of the company’s stock worth $36,113,000 after buying an additional 596,255 shares during the last quarter. Invesco Ltd. increased its holdings in Crispr Therapeutics by 42.7% in the first quarter. Invesco Ltd. now owns 190,307 shares of the company’s stock worth $8,071,000 after buying an additional 56,928 shares during the last quarter. Finally, Engineers Gate Manager LP increased its holdings in Crispr Therapeutics by 88.4% in the first quarter. Engineers Gate Manager LP now owns 20,510 shares of the company’s stock worth $870,000 after buying an additional 9,621 shares during the last quarter. 55.29% of the stock is owned by hedge funds and other institutional investors.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

See Also: What are the qualifications of a portfolio manager?

The Fly

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.